TNFSF13B and Graves disease: Given the reported elevation of serum BAFF concentrations in Graves’ disease patients (68, 69) and the expression of BAFF on thyroid cells in patients with autoimmune diseases or a nodular goiter (70, 71), belimumab potentially exhibits beneficial effects in reducing disease activity in Graves’ disease and TAO.